Bioxcel Therapeutics Logo

Advisors

Artificial Intelligence (AI)

Joscha Bach

Cognitive Scientist and Artificial Intelligence (AI) Researcher

Joscha Bach is a cognitive scientist and artificial intelligence (AI ) researcher. He obtained his Ph.D. in Cognitive Science from the University of Osnabrück and worked as a lecturer…

Novacek

Vít Novacek

Associate Professor at Faculty of Informatics, Masaryk University, Czech Republic

Vít Novacek is Associate Professor at Faculty of Informatics, Masaryk University, Czech Republic. He is also affiliated with the Data Science Institute at National University…

Corporate/Clinical

sheila_gujrathi

Sheila Gujrathi, M.D.

Co-Founder and Chief Executive Officer, Gossamer Bio

Dr. Gujrathi is the Co-Founder and Chief Executive Officer of Gossamer Bio. She most recently served as Chief Medical Officer of Receptos, an immunology-focused biotechnology…

Rajiv Patni, M.D.

Strategic Clinical Advisor to CEO and Board of Directors

Dr. Rajiv Patni was Chief Research and Development Officer at Reata Pharmaceuticals a commercial-stage company recently acquired by Biogen. Previously, he was a successful…

Immuno-oncology

Rahul Aggarwal, MD

Associate Director for Clinical Sciences, UCSF Helen Diller Family Comprehensive Cancer Center; Associate Professor of Hematology/Oncology, UCSF

Dr. Rahul Aggarwal is a Medical Oncologist within the Division of Hematology/Oncology at the University of California San Francisco (UCSF). His clinical practice focuses…

Daniel D. Von Hoff, M.D., F.A.C.P.

Executive Vice President and Distinguished Professor at the Translational Genomics Research Institute (TGen)

Daniel D. Von Hoff, M.D., F.A.C.P. is currently Executive Vice President and Distinguished Professor at the Translational Genomics Research Institute (TGen) in Phoenix, Arizona…

Louis M. Weiner, M.D.

Director, Georgetown Lombardi Comprehensive Cancer Center

Dr. Louis Weiner is Director of Georgetown Lombardi Comprehensive Cancer Center, one of 49 National Cancer Institute (NCI)-designated comprehensive cancer…
Scroll to Top

Joscha Bach

Cognitive Scientist and Artificial Intelligence (AI ) Researcher

Joscha Bach is a cognitive scientist and artificial intelligence (AI ) researcher. He obtained his Ph.D. in Cognitive Science from the University of Osnabrück and worked as a lecturer and researcher at Humboldt University of Berlin, MIT Media Lab, and the Harvard Program for Evolutionary Dynamics. He authored the book Principles of Synthetic Intelligence and co-founded several startup companies. Dr. Bach is currently working as a Principal AI Engineer at Intel Labs in California.

Novacek

Vít Novacek

Associate Professor at Faculty of Informatics, Masaryk University, Czech Republic

Vít Novacek is Associate Professor at Faculty of Informatics, Masaryk University, Czech Republic. He is also affiliated with the Data Science Institute at National University of Ireland, Galway and Masaryk Memorial Cancer Institute, primarily helping coordinate strategic activities related to biomedical artificial intelligence (AI) applications. He holds a Ph.D. from NUI Galway and other degrees from Masaryk University. His research revolves around discovery informatics based on machine learning, explainable AI, and text mining, with an emphasis on oncology use cases. He has published 35+ peer-reviewed papers in high-profile journals and conferences. Dr. Novacek has helped acquire and coordinate multiple research projects working with national, European, U.S., and Japanese partners in academia and industry. He has secured approximately $1.8 million for his research groups and has three patents granted and three pending (in the EU, U.S. and JP jurisdictions). Dr. Novacek also has taught undergraduate and postgraduate courses on AI, machine learning, bioinformatics, and health informatics.

sheila_gujrathi

Sheila Gujrathi, M.D.

Co-Founder and Chief Executive Officer, Gossamer Bio

Dr. Gujrathi is the Co-Founder and Chief Executive Officer of Gossamer Bio. She most recently served as Chief Medical Officer of Receptos, an immunology-focused biotechnology company acquired by Celgene in 2015 for $7.2 billion. At Receptos, she built the clinical development organization and advanced the pipeline of drug candidates, including Phase 3 programs in multiple sclerosis and ulcerative colitis. Previously, Dr. Gujrathi was Vice President of the Global Clinical Development Group in Immunology at Bristol-Myers Squibb (BMS). There she led late-stage clinical development and supported regulatory filings for Orencia® and Nulojix®. She was also responsible for development of other assets in the BMS immunology clinical pipeline, and advised the strategies for discovery, early development, and external business development within the immuno-science franchise. Prior to BMS, Dr. Gujrathi held roles in the immunology, tissue growth, and repair clinical development groups at Genentech and served as the Avastin franchise team leader. Earlier in her career, she was a management consultant in McKinsey & Company’s healthcare practice. Dr. Gujrathi received her B.S. in biomedical Engineering and M.D. from Northwestern University in the Honors Program in Medical Education. She completed her internal medicine internship and residency at Brigham and Women’s Hospital, Harvard Medical School, and additional fellowship training in Allergy/Immunology at UCSF and Stanford. She previously served on the Board of Directors of Ambrx, which was acquired in 2015.

Rajiv Patni, M.D.

Strategic Clinical Advisor to CEO and Board of Directors

Dr. Rajiv Patni was Chief Research and Development Officer at Reata Pharmaceuticals, a commercial-stage company recently acquired by Biogen. Previously, he was a successful Chief Medical Officer at several public, small-cap, commercial-stage biopharmaceutical companies: Adamas, Portola, and Global Blood Therapeutics. He joined these companies at an inflection point in their R&D growth trajectories and contributed to their acquisition by larger companies. Earlier in his career, Dr. Patni had roles of increasing responsibility at Pfizer, Roche, and Actelion. 

Over his 23-year industry tenure in global product development, Dr. Patni has contributed to the development of 21 NCEs for both common and, most recently, rare diseases. His experience in fostering successful team efforts at these different companies contributed to the approval of 10 medicines, from the U.S. FDA, EMA, and other regulatory agencies. Dr. Patni received his M.D. degree from the Mount Sinai School of Medicine in New York City as part of an accelerated B.S. /M.D. program. He completed his internal medicine residency and adult cardiology fellowship at the Albert Einstein College of Medicine, also in New York City, where he continued as an attending physician-scientist before joining the biopharmaceutical industry. 

Rahul

Rahul Aggarwal, MD

Associate Director for Clinical Sciences, UCSF Helen Diller Family Comprehensive Cancer Center; Associate Professor of Hematology/Oncology, UCSF

Dr. Rahul Aggarwal is a Medical Oncologist within the Division of Hematology/Oncology at the University of California San Francisco (UCSF). His clinical practice focuses on patients with advanced solid tumor malignancies with a particular emphasis on genitourinary malignancies including prostate, kidney, bladder, and testicular cancer. He serves as the Co-Leader for the GU Medical Oncology program at UCSF. His research focus is on developing novel therapies and imaging modalities for patients with advanced solid tumor malignancies, with a focus on patients with advanced prostate cancer.

Dr. Aggarwal has a B.A. in Psychology from Northwestern University and M.D. from Northwestern University Feinberg School of Medicine.
Daniel D. Von Hoff

Daniel D. Von Hoff, M.D., F.A.C.P.

Executive Vice President and Distinguished Professor at the Translational Genomics Research Institute (TGen)

Daniel D. Von Hoff, M.D., F.A.C.P. is currently Executive Vice President and Distinguished Professor at the Translational Genomics Research Institute (TGen) in Phoenix, Arizona. He is also Chief Scientific Officer for HonorHealth Clinical Research Institute and Chair of the Early Drug Development Committee at McKesson Specialty Health, U.S. Oncology Research. He is also Professor of Medicine, Mayo Clinic Scottsdale, Arizona. Dr. Von Hoff’s major interest is in the development of new anticancer agents, both in the clinic and in the laboratory. He and his colleagues were involved in the beginning of the development of many FDA-approved agents we now use routinely, including: mitoxantrone, fludarabine, paclitaxel, docetaxel, gemcitabine, irinotecan, nelarabine, capecitabine, lapatinib, isomeric, nab-paclitaxel, nal-IRI, and others. His clinical trial work has led to the approval of three of the four drugs approved by the FDA for treatment of patients with advanced pancreatic cancer.

At present, he and his colleagues are concentrating on the development of molecularly targeted therapies particularly for patients with advanced pancreatic cancer. Dr. Von Hoff has published more than 767 papers, 140 book chapters, and over 1190 abstracts. He received the 2010 David A. Karnofsky Memorial Award from the American Society of Clinical Oncology for his outstanding contributions to cancer research leading to significant improvement in patient care. Dr. Von Hoff was appointed to President Bush’s National Cancer Advisory Board in 2004-2010. He is past President of the American Association for Cancer Research (the world’s largest cancer research organization), a Fellow of the American College of Physicians, and a member and past board member of the American Society of Clinical Oncology. He is a founder of ILEX™ Oncology, Inc. (acquired by Genzyme after ILEX had two agents, alemtuzumab and clofarabine, approved by the FDA for patients with leukemia). Dr. Von Hoff is founder and Editor Emeritus of Investigational New Drugs –The Journal of New Anticancer Agents – and past Editor-in-Chief of Molecular Cancer Therapeutics. He is a co-founder of the AACR/ASCO Methods in Clinical Trial Cancer Research Workshop, which has graduated more than 2000 clinical trial physicians. He is also proud to have been a mentor and teacher for multiple medical students, medical oncology fellows, graduate students, and post-doctoral fellows.
Louis M

Louis M. Weiner, M.D.

Director, Georgetown Lombardi Comprehensive Cancer Center

Dr. Louis Weiner is Director of Georgetown Lombardi Comprehensive Cancer Center, one of 49 National Cancer Institute (NCI)-designated comprehensive cancer centers in the United States. He holds the Francis L. and Charlotte G. Gragnani Chair and is Professor of Oncology and Chair of the Department of Oncology at Georgetown University Medical Center. He also serves as Director of the MedStar Georgetown Cancer Institute, a cancer service line serving patients in the Washington DC and Baltimore metropolitan areas. He is responsible for the operation and development of the cancer center, including its research, clinical, and educational missions. The clinical mission includes leading the MedStar-Georgetown Cancer Network in the metropolitan Washington area. Dr. Weiner is known for his laboratory and clinical research focusing on new therapeutic approaches that mobilize the patient’s immune system to fight cancer using monoclonal antibodies and related modalities of therapy. His current research focuses on identifying and therapeutically exploiting mechanisms employed by malignant cells to combat immune destruction, with a focus on pancreatic cancer.

Prior to joining Georgetown Lombardi as director in 2008, Dr. Weiner served as Chairman of the medical oncology department and Vice President for Translational Research at Fox Chase Cancer Center in Philadelphia and served as professor in the department of medicine at Temple University School of Medicine. He is an active member of the American Society of Clinical Oncology and the American Association for Cancer Research (AACR) and founded the AACR Cancer Immunology Working Group. He has served as chair of the NCI Board of Scientific Counselors for Clinical Sciences and Epidemiology and as a member of the NCI Clinical Trials Advisory Committee (CTAC). He also served on the NCI’s blue ribbon panel working group on immunotherapy for the National Cancer Moonshot Initiative and Advisory Panel of the National Institutes of Health (NIH) Center for Scientific Research (CSR), which administers NIH research grants. He is recipient of the 2019 AACR Distinguished Public Service Award.

Dr. Weiner earned his bachelor’s degree in biology with honors from the University of Pennsylvania and his M.D. from Mount Sinai School of Medicine. After completing his internship, residency, and service as chief medical resident at the University of Vermont’s Medical Center Hospital, he held clinical and research fellowships in hematology and oncology at Tufts University School of Medicine in Boston.

The information provided on this site is intended for use by healthcare professionals practicing in the US. The dissemination of this information may be subject to different medical andregulatory requirements in other countries. This web site is intended to help healthcare professionals practicing in the US and Bioxcel Therapeutics authorized persons find scientifically balanced, evidence-based information about Bioxcel Therapeutics drugs, submit a question, ask for field medical follow-up, and explore links to professional and patient support resources.